What type of study is this?

This is a Human Clinical Trial study (also classified as: Mixed-Methods, Pre-Registered Trial).

What question did this study set out to answer?

This research aims to explore the proteogenomic characteristics of NPM1-mutated AML and their clinical implications.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

This research aims to explore the proteogenomic characteristics of NPM1-mutated AML and their clinical implications.
Conducted a proteomic analysis on bone marrow blasts from 284 patients with NPM1-mutated AML.
Analyzed protein expression of 7,223 proteins and performed targeted DNA sequencing of 263 genes.
Compared treatment outcomes with intensive chemotherapy and gemtuzumab ozogamicin.
Identified a differentiation gradient associated with genetic alterations in AML.
High BCL2 expression correlated with immature NPM1-mutated AML and venetoclax sensitivity.
A high Mito-score predicted worse event-free and overall survival, highlighting its prognostic significance.

No takes yet. Share an insight, caveat, or question.

Proteogenomic analysis identifies differentiation states and mitochondrial metabolism as key factors impacting outcomes in NPM1-mutated AML patients.

Jakob et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Proteogenomic analysis identifies differentiation states and mitochondrial metabolism as key factors impacting outcomes in NPM1-mutated AML patients.